Jim Manzi, Steve Lundy | GenomeWeb

Jim Manzi, Steve Lundy

Premium
Thermo Fisher Scientific this week named Jim Manzi non-executive chairman of its board. He succeeds Paul Meister, who retired as chairman on April 10. Manzi was chairman of Thermo Electron from December 2003 through Nov. 9, 2006, when Thermo completed its merger with Fisher Scientific. He is currently chairman of Stonegate Capital. He was president, chairman, and CEO of Lotus Development from 1984 to 1995, when it was acquired by IBM.
 

 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.